Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:31 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Behavioral Effects of Drugs (Inpatient): 38
NCT03954938 · William Stoops · EARLY_PHASE1 · terminated · last registry update 2024-05-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “COVID-19” | – | Registry record, William Stoops |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SCN1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-05-23Results posted on the registry: University of Massachusetts, Worcester, Brexpiprazole (NCT03526354)
- 2025-04-03Results posted on the registry: Joshua A. Lile, Ph.D., Cocaine HCl (NCT04296006)
- 2025-02-25Results posted on the registry: National Institute on Drug Abuse (NIDA), a drug against SCN1A (NCT02927236)
- 2025-02-25Also stopped (terminated): National Institute on Drug Abuse (NIDA), a drug against SCN1A (NCT02927236)
- 2025-02-20Results posted on the registry: Medical University of South Carolina, a drug against SCN1A (NCT04907357)
- 2025-02-07Also stopped (terminated): Salvatore Campanella, N-acetylcysteine + Lactose powder (NCT03423667)
- 2025-02-06Results posted on the registry: Atrial Fibrillation Network, Edoxaban + ASA (NCT02618577)
- 2025-02-06Also stopped (terminated): Atrial Fibrillation Network, Edoxaban + ASA (NCT02618577)
- 2025-01-09Results posted on the registry: Mayo Clinic, a drug against SCN1A (NCT05535257)
- 2024-12-12Results posted on the registry: Yale University, cannabis (NCT02817698)
- 2024-11-06Results posted on the registry: Tyme, Inc, SM-88 used with MPS (methoxsalen, phenytoin, sirolimus) + Capecitabine, Gemcitabine, and 5-FU (NCT03512756)
- 2024-11-06Also stopped (terminated): Tyme, Inc, SM-88 used with MPS (methoxsalen, phenytoin, sirolimus) + Capecitabine, Gemcitabine, and 5-FU (NCT03512756)
- 2024-10-09Phase 3 first posted: University of California, San Francisco, IM naltrexone (NCT06633900)
- 2024-10-09Results posted on the registry: Imperial College London, Anti-Arrhythmic therapy (NCT02459574)
- 2024-08-09Results posted on the registry: University of Illinois Chicago, d-amphetamine + Placebo (for d-amphetamine) (NCT02773212)
- 2024-08-01Results posted on the registry: William Stoops, a drug against SCN1A (NCT03224546)
- 2024-07-16Results posted on the registry: Yale University, a drug against SCN1A (NCT03527485)
- 2024-07-16Also stopped (suspended): New York State Psychiatric Institute, CI-581a + CI-581b (NCT03344419)
- 2024-07-03Results posted on the registry: Yale University, Pregnenolone (PREG) + Placebos (NCT03953612)
- 2024-06-17Phase 3 first posted: Alexandria University, Benoxinate Hydrochloride + artificial tear (Sodium Hyaluronate 2 mg/ml) eye drops. (NCT06461975)
- 2024-06-05Phase 3 first posted: Copenhagen University Hospital, Rigshospitalet, Cociane hydrochloride 4% + Lidocaine 4% (NCT06443255)
- 2024-05-29Also stopped (terminated): Columbia University, a drug against SCN1A (NCT01794936)
- 2024-04-23Results posted on the registry: London Vision Clinic, Tobramycin and dexamethasone + Ofloxacin (NCT02528123)
- 2024-04-23Also stopped (withdrawn): Yong Seog Oh, Propafenone + Indenol (NCT03561935)
- 2024-04-08Also stopped (terminated): UCB Biopharma SRL, Brivaracetam (BRV) intravenous (iv) + Brivaracetam (BRV) oral (NCT03325439)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision